|
|
Article: In New Clinical Studies, Actonel(TM) (risedronate) Builds Bone Mass and Reduces Incidence of Vertebral Fractures at One Year by 70 Percent in Men and Women on Chronic Corticosteroid Therapy.
- Article from:
- PR Newswire
- Article date:
- November 11, 1998
CopyrightCOPYRIGHT 1998 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Combined Studies Also Show 1 in 6 Patients Taking Chronic Corticosteroids Face
Increased Risk of Vertebral Fractures
SAN DIEGO, Nov. 11 /PRNewswire/ -- Data from two new studies show that Actonel(TM) (risedronate) reduced the incidence of vertebral fractures by up to 70 percent at 12 months, built and prevented the loss of bone mass, and showed gastrointestinal tolerability similar to placebo in men and women on chronic corticosteroid therapy. The studies were presented separately and in a pooled analysis at the annual meeting of the American College of Rheumatology (ACR).
Actonel, a novel, pyridinyl bisphosphonate invented and developed by ...